Project Grant R42AG097309
Award Date 9/20/25
Completion Date 9/19/26
Dollars Obligated $493K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Concord, MA 01742, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...
- The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...
- This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $506,061 to Redwood Neuro Inc. to develop an innovative blood-based diagnostic platform called SIMOLISA. The goal is to revolutionize Alzheimer's disease (AD) diagnostics by enabling ultra-sensitive and affordable detection of critical AD biomarkers such as p-tau proteins and β-amyloid. Unlike current high-cost systems, SIMOLISA utilizes cost-effective materials and...
- This Project Grant award of $500,000 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to support the development of an in vivo imaging platform called the VasoVue Lab. The objective is to enable rapid, non-invasive assessment of cerebrovascular dysfunction, which is known to be impaired in Alzheimer's disease (AD). The proposed solution will use laser speckle contrast imaging to monitor blood flow changes in the retina and brain...
- This federal Project Grant award of $495,731.00, awarded on September 20, 2025 by the National Institute on Aging (CFDA 93.866 Aging Research program), supports the evaluation of Viewmind's ability to detect beta-amyloid and tau burden consistent with Alzheimer's disease in persons with mild cognitive impairment (MCI) using machine learning, virtual reality, and eye-tracking technology. The project aims to develop a non-invasive, cost-effective, and rapid diagnostic tool that can accurately...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Adeptrix Corp. a $499,940 Project Grant on Sep 11, 2025 to develop TAUTRACE, an ultrasensitive immunoassay platform for quantifying distinct molecular forms of the tau protein in cerebrospinal fluid and plasma at femtogram/milliliter levels. This innovative technology enables the detection of single ions, allowing for the quantification of tau proteoforms as critical Alzheimer's disease...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $307,538 to Sage Cerebrovascular Diagnostics, Inc. to develop and validate a novel, minimally invasive diagnostic assay to discriminate Alzheimer's disease from vascular dementia. The award aims to: 1) establish the assay's performance characteristics in a clinical laboratory environment, 2) identify the optimal at-home sample collection methodology, and 3) determine the assay's sensitivity...
- This federal Project Grant award of $437,250.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support the development of new imaging tools to study the various forms of the tau protein, which is implicated in Alzheimer's disease. The goal is to create a peptide-based probe that can detect tau in its soluble, liquid-liquid phase separation, and liquid-solid phase separation states within living cells using an aggregation-induced emission (AIE) approach. This...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...